HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Proposals for the objective indices for evaluating the differentiation of leukemic cells by all-trans retinoic acid in the patients with acute promyelocytic leukemia].

Abstract
All-trans retinoic acid (ATRA) is widely used as a differentiation-inducing agent for acute promyelocytic leukemia (APL). However, one of the problems with this therapy is the difficulty in evaluating the extent of differentiation of leukemic cells. To determine objective indices for differentiation which can be used for judging complete remission, we treated 18 patients with acute promyelocytic leukemia, and performed sequential analysis of bone marrow, karyotype, RAR alpha gene rearrangement and PML-RAR alpha fusion gene transcript. The karyotype, RAR alpha rearrangement and PML-RAR alpha transcript returned to a normal pattern on days 31, 2, 34.8 and 47.6, respectively. We defined and analyzed maturation index (MI) by bone marrow findings as follows; (metamylocyte + band neutrophil + segmented neutrophil) (%)/(myeloblast + promyelocyte + myelocyte) (%). MI increased along with the differentiation of leukemic cells, and the days for MI exceeding 2 well correlated with the normalization of karyotype. These results suggested that MI can be used as an index of differentiation during ATRA therapy.
AuthorsH Nakajima, M Kizaki, N Takayama, Y Kawai, K Watanabe, S Okamoto, Y Ikeda
Journal[Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 37 Issue 3 Pg. 208-13 (Mar 1996) ISSN: 0485-1439 [Print] Japan
PMID8727344 (Publication Type: Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Tretinoin
Topics
  • Adolescent
  • Adult
  • Bone Marrow Cells
  • Cell Differentiation (drug effects)
  • Child
  • Female
  • Gene Rearrangement
  • Humans
  • Karyotyping
  • Leukemia, Promyelocytic, Acute (drug therapy, genetics, pathology)
  • Male
  • Middle Aged
  • Remission Induction
  • Tretinoin (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: